These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 11806981)

  • 1. De novo CD5+ diffuse large B-cell lymphoma: a clinicopathologic study of 109 patients.
    Yamaguchi M; Seto M; Okamoto M; Ichinohasama R; Nakamura N; Yoshino T; Suzumiya J; Murase T; Miura I; Akasaka T; Tamaru J; Suzuki R; Kagami Y; Hirano M; Morishima Y; Ueda R; Shiku H; Nakamura S
    Blood; 2002 Feb; 99(3):815-21. PubMed ID: 11806981
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Sub-classification of diffuse large B-cell lymphoma by semi-quantification of the CD5 expression with flow cytometric analysis].
    Manabe N; Yamaoka G; Ohnishi H; Arai T; Nakaishi H; Kajikawa T; Kubota Y; Tanaka T; Kitanaka A; Waki M; Kawakami K; Nagai M; Ishida T; Taminato T
    Rinsho Byori; 2002 Sep; 50(9):906-11. PubMed ID: 12386970
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravascular large B-cell lymphoma (IVLBCL): a clinicopathologic study of 96 cases with special reference to the immunophenotypic heterogeneity of CD5.
    Murase T; Yamaguchi M; Suzuki R; Okamoto M; Sato Y; Tamaru J; Kojima M; Miura I; Mori N; Yoshino T; Nakamura S
    Blood; 2007 Jan; 109(2):478-85. PubMed ID: 16985183
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Large cell variants of CD5+, CD23- B-cell lymphoma/leukemia.
    Dunphy CH; Perkins SL
    Arch Pathol Lab Med; 2001 Apr; 125(4):513-8. PubMed ID: 11260626
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of CD29 on lymphoma cells and/or CD36 on microvascular endothels correlates with high serum LDH level in diffuse large B-cell lymphomas (DLBCLs) and is frequent in de novo CD5-positive DLBCLs.
    Ueno S; Yamaguchi M; Kimura M; Odagiri H; Shiraki K; Uemoto S; Nakamura N; Zhang W; Shiku H; Kobayashi T
    Int J Oncol; 2005 Nov; 27(5):1241-6. PubMed ID: 16211218
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of CD5/Cyclin D1 Double-negative Pleomorphic Mantle Cell Lymphoma: A Clinicopathologic, Genetic, and Gene Expression Study.
    Chuang WY; Chang ST; Yuan CT; Chang GJ; Chang H; Yeh CJ; Ueng SH; Kao HW; Wang TH; Wan YL; Shih LY; Chuang SS; Hsueh C
    Am J Surg Pathol; 2020 Feb; 44(2):232-240. PubMed ID: 31688139
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of CD5/SOX11 double-negative pleomorphic mantle cell lymphoma.
    Chuang WY; Chang H; Shih LY; Lin TC; Yeh CJ; Ueng SH; Kuo MC; Kao HW; Liu H; Chang ST; Lee CL; Huang KP; Wang TH; Wan YL; Yu JS; Hsueh C; Chuang SS
    Virchows Arch; 2024 Aug; 485(2):323-334. PubMed ID: 38733379
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Significance of cyclin D1 overexpression for the diagnosis of mantle cell lymphoma: a clinicopathologic comparison of cyclin D1-positive MCL and cyclin D1-negative MCL-like B-cell lymphoma.
    Yatabe Y; Suzuki R; Tobinai K; Matsuno Y; Ichinohasama R; Okamoto M; Yamaguchi M; Tamaru J; Uike N; Hashimoto Y; Morishima Y; Suchi T; Seto M; Nakamura S
    Blood; 2000 Apr; 95(7):2253-61. PubMed ID: 10733493
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma.
    Colomo L; López-Guillermo A; Perales M; Rives S; Martínez A; Bosch F; Colomer D; Falini B; Montserrat E; Campo E
    Blood; 2003 Jan; 101(1):78-84. PubMed ID: 12393466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinicopathologic significance and therapeutic implication of de novo CD5+ diffuse large B-cell lymphoma.
    Tang H; Zhou H; Wei J; Liu H; Qian W; Chen X
    Hematology; 2019 Dec; 24(1):446-454. PubMed ID: 31072235
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Centroblastic and centroblastic/centrocytic lymphoma associated with a prominent epithelioid granulomatous response: a clinicopathologic study of 50 cases.
    Kojima M; Nakamura S; Ichimura K; Suzuki R; Kagami Y; Kondo E; Motoori T; Hosomura Y; Oyama T; Itoh H; Ban S; Yoshida K; Ohno Y; Shimizu K; Masawa N; Sugihara S
    Mod Pathol; 2002 Jul; 15(7):750-8. PubMed ID: 12118113
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular and immunological dissection of diffuse large B cell lymphoma: CD5+, and CD5- with CD10+ groups may constitute clinically relevant subtypes.
    Harada S; Suzuki R; Uehira K; Yatabe Y; Kagami Y; Ogura M; Suzuki H; Oyama A; Kodera Y; Ueda R; Morishima Y; Nakamura S; Seto M
    Leukemia; 1999 Sep; 13(9):1441-7. PubMed ID: 10482997
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [De novo CD5-positive diffuse large B-cell lymphoma with leukemic dissemination diagnosed by immunohistochemical examinations of bone marrow clot sections].
    Yoshida K; Kayano H; Akiba M; Kishimoto K; Takahashi N; Sugahara Y; Kawai N; Matsuda A; Hirashima K; Suzuki T; Bessho M
    Rinsho Ketsueki; 2002 Oct; 43(10):943-8. PubMed ID: 12462031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD5 expression correlates with inferior survival and enhances the negative effect of p53 overexpression in diffuse large B-cell lymphoma.
    Zhao P; Li L; Zhou S; Qiu L; Qian Z; Liu X; Meng B; Zhang H
    Hematol Oncol; 2019 Oct; 37(4):360-367. PubMed ID: 31359442
    [TBL] [Abstract][Full Text] [Related]  

  • 15. De novo CD5+ diffuse large B-cell lymphoma: results of a detailed clinicopathological review in 120 patients.
    Yamaguchi M; Nakamura N; Suzuki R; Kagami Y; Okamoto M; Ichinohasama R; Yoshino T; Suzumiya J; Murase T; Miura I; Ohshima K; Nishikori M; Tamaru J; Taniwaki M; Hirano M; Morishima Y; Ueda R; Shiku H; Nakamura S
    Haematologica; 2008 Aug; 93(8):1195-202. PubMed ID: 18556402
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinicopathologic characteristics and treatment outcome of the addition of rituximab to chemotherapy for CD5-positive in comparison with CD5-negative diffuse large B-cell lymphoma.
    Niitsu N; Okamoto M; Tamaru JI; Yoshino T; Nakamura N; Nakamura S; Ohshima K; Nakamine H; Hirano M
    Ann Oncol; 2010 Oct; 21(10):2069-2074. PubMed ID: 20231297
    [TBL] [Abstract][Full Text] [Related]  

  • 17. De novo CD5 positive diffuse large B-cell lymphomas with bone marrow involvement in Korean.
    Kong SY; Cho EH; Woo HY; Park Q; Ko YH; Kim SH
    J Korean Med Sci; 2004 Dec; 19(6):815-9. PubMed ID: 15608391
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Large cell lymphoma transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma. A flow cytometric analysis of seven cases.
    Kroft SH; Dawson DB; McKenna RW
    Am J Clin Pathol; 2001 Mar; 115(3):385-95. PubMed ID: 11242795
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and prognostic significance of aberrant T-cell marker expression in 225 cases of de novo diffuse large B-cell lymphoma and 276 cases of other B-cell lymphomas.
    Tsuyama N; Ennishi D; Yokoyama M; Baba S; Asaka R; Mishima Y; Terui Y; Hatake K; Takeuchi K
    Oncotarget; 2017 May; 8(20):33487-33500. PubMed ID: 28380441
    [TBL] [Abstract][Full Text] [Related]  

  • 20. De novo CD5-positive and Richter's syndrome-associated diffuse large B cell lymphomas are genotypically distinct.
    Matolcsy A; Chadburn A; Knowles DM
    Am J Pathol; 1995 Jul; 147(1):207-16. PubMed ID: 7541611
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.